<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00100698</url>
  </required_header>
  <id_info>
    <org_study_id>DK63639</org_study_id>
    <secondary_id>R01DK063639</secondary_id>
    <nct_id>NCT00100698</nct_id>
  </id_info>
  <brief_title>Physiologic Growth Hormone Effects in HIV Lipodystrophy</brief_title>
  <official_title>Physiologic Growth Hormone Effects in HIV Lipodystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate long-term, low-dose growth hormone administration in HIV-infected
      patients with reduced growth hormone (GH) secretion and increased visceral adiposity. We
      hypothesize that low-dose growth hormone will reduce visceral fat. Secondary endpoints will
      include measures of insulin-like growth factor-1 (IGF-1), glucose homeostasis, lipids, blood
      pressure,bone density, cardiovascular risk and safety parameters.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will investigate long-term, low-dose growth hormone administration in HIV-infected
      patients with reduced growth hormone (GH) secretion and increased visceral adiposity. We
      hypothesize that low-dose growth hormone will reduce visceral fat preferentially over
      subcutaneous fat, and increase lean body mass. Secondary endpoints will include measures of
      IGF-1, glucose homeostasis, lipids, blood pressure,bone density, cardiovascular risk and
      safety parameters. Dosing of growth hormone will be based on patients' IGF-1 levels and will
      not exceed 6mcg/kg/day.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Visceral Adipose Tissue Area From Baseline to 18 Months</measure>
    <time_frame>18 months</time_frame>
    <description>change in visceral adipose tissue area as measured by single-slice abdominal computed tomographic scan</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Insulin-like Growth Factor-I From Baseline to 18 Months</measure>
    <time_frame>18 months</time_frame>
    <description>Change in insulin-like growth factor-1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Trunk Fat</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fasting Glucose</measure>
    <time_frame>18 months</time_frame>
    <description>change in fasting glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Trunk to Extremity Ratio</measure>
    <time_frame>18 months</time_frame>
    <description>change in trunk to extremity ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Triglycerides</measure>
    <time_frame>18 months</time_frame>
    <description>Change in triglycerides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Subcutaneous Adipose Tissue</measure>
    <time_frame>18 months</time_frame>
    <description>Change in subcutaneous adipose tissue</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CD4 Cells</measure>
    <time_frame>18 months</time_frame>
    <description>Change in CD4 cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Logarithm HIV Viral Load</measure>
    <time_frame>18 months</time_frame>
    <description>Change in logarithm base 10 HIV viral load</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Lean Body Mass</measure>
    <time_frame>18 months</time_frame>
    <description>change in lean body mass</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life Score From the Medical Outcomes Study-HIV Survey From Baseline to 18 Months</measure>
    <time_frame>18 months</time_frame>
    <description>Change in quality of life score was measured by the Medical Outcomes Study-HIV (MOS-HIV)survey. The MOS-HIV asks patients to report on health-related quality of life and physical function from the past 4 days. The scoring range is 0-100, and a higher score indicates better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Diastolic Blood Pressure</measure>
    <time_frame>18 months</time_frame>
    <description>Change in diastolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Adiponectin</measure>
    <time_frame>18 months</time_frame>
    <description>Change in adiponectin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Carotid Intima Media Thickness (IMT)</measure>
    <time_frame>18 months</time_frame>
    <description>change in carotid intima media thickness (IMT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Mass Index</measure>
    <time_frame>18 months</time_frame>
    <description>Change in body mass index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Extremity Fat</measure>
    <time_frame>18 months</time_frame>
    <description>Change in extremity fat</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 2-hour Glucose</measure>
    <time_frame>18 months</time_frame>
    <description>Change in 2-hour glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Systolic Blood Pressure</measure>
    <time_frame>18 months</time_frame>
    <description>Change in systolic blood pressure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>AIDS</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>recombinant human growth hormone subcutaneously once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo subcutaneously once a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>recombinant human growth hormone</intervention_name>
    <description>growth hormone dosed by weight and IGF-1 level,subcutaneously once a day, 18 months</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Serostim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo subcutaneously once a day, 18 months</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women age 18-60

          -  Previously diagnosed HIV infection

          -  Stable antiviral regimen for at least 12 weeks prior to enrollment

          -  Waist-to-hip ratio &gt;0.90 for men and &gt;0.85 for women

          -  Evidence of at least one of the following recent changes: *increased abdominal girth,

             *relative loss of fat in the extremities, *relative loss of fat in the face

          -  Simulated peak GH response to arginine/GHRH of less than 7.5 mcg/dL

        Exclusion Criteria:

          -  Use of Megace, anti-diabetic agents, GH, or other anabolic agents, pharmacologic
             glucocorticoid (prednisone &gt;5 mg/day or its equivalent) for 3 months prior to
             enrollment. Patients on a standard dose of testosterone for documented hypogonadism
             will be allowed to enter the protocol. Women taking standard estrogen replacement
             therapy for &gt;3 months will be allowed in the study.

          -  Diabetes mellitus

          -  Other severe chronic illness

          -  HgB &lt;9.0 g/dL, creatinine &gt;1.4 mg/dL, or PSA &gt;4 ng/mL

          -  Positive BHCG or failure to use appropriate birth control during study. Acceptable
             methods include oral contraceptives, depo provera or combined progesterone-estrogen
             injections, transdermal contraceptive patches, IUD's, barrier devices (condoms,
             diaphragms), and abstinence.

          -  Carpal tunnel syndrome

          -  Active malignancy or history of pituitary malignancy, history of colon cancer or
             prostate malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Grinspoon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MGH</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2005</study_first_submitted>
  <study_first_submitted_qc>January 4, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2005</study_first_posted>
  <results_first_submitted>April 9, 2010</results_first_submitted>
  <results_first_submitted_qc>July 19, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 22, 2010</results_first_posted>
  <last_update_submitted>July 22, 2010</last_update_submitted>
  <last_update_submitted_qc>July 22, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 27, 2010</last_update_posted>
  <responsible_party>
    <name_title>Steven Grinspoon, MD</name_title>
    <organization>Massachusetts General Hospital</organization>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>lipodystrophy</keyword>
  <keyword>growth hormone</keyword>
  <keyword>visceral fat</keyword>
  <keyword>IGF-I</keyword>
  <keyword>Treatment Experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Lipodystrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients with HIV and lipodystrophy were recruited between November 2003 and March 2006 via community advertisement, HIV support and advocacy groups, and infectious disease or primary care physician referral.</recruitment_details>
      <pre_assignment_details>Patients who do not meet growth hormone inclusion criteria were excluded from the trial before assignment to groups.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Recombinant Human Growth Hormone</title>
          <description>recombinant human growth hormone starting at 2 micrograms/kilograms/day subcutaneously and increased to maximum dose of 6 micrograms/kilograms/day subcutaneously</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>placebo subcutaneously once a day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Recombinant Human Growth Hormone</title>
          <description>recombinant human growth hormone starting at 2 micrograms/kilograms/day subcutaneously and increased to maximum dose of 6 micrograms/kilograms/day subcutaneously</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>placebo subcutaneously once a day</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
            <count group_id="B2" value="29"/>
            <count group_id="B3" value="56"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.7" spread="7.9"/>
                    <measurement group_id="B2" value="47.4" spread="6.1"/>
                    <measurement group_id="B3" value="47.1" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Visceral Adipose Tissue Area From Baseline to 18 Months</title>
        <description>change in visceral adipose tissue area as measured by single-slice abdominal computed tomographic scan</description>
        <time_frame>18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Recombinant Human Growth Hormone</title>
            <description>recombinant human growth hormone starting at 2 micrograms/kilograms/day subcutaneously and increased to maximum dose of 6 micrograms/kilograms/day subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo subcutaneously once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Visceral Adipose Tissue Area From Baseline to 18 Months</title>
          <description>change in visceral adipose tissue area as measured by single-slice abdominal computed tomographic scan</description>
          <units>centimeters squared</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22" spread="6"/>
                    <measurement group_id="O2" value="-4" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.049</p_value>
            <method>repeated measures mixed effects ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-22</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>6</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-38</ci_lower_limit>
            <ci_upper_limit>-0.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Insulin-like Growth Factor-I From Baseline to 18 Months</title>
        <description>Change in insulin-like growth factor-1</description>
        <time_frame>18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Recombinant Human Growth Hormone</title>
            <description>recombinant human growth hormone starting at 2 micrograms/kilograms/day subcutaneously and increased to maximum dose of 6 micrograms/kilograms/day subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo subcutaneously once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Insulin-like Growth Factor-I From Baseline to 18 Months</title>
          <description>Change in insulin-like growth factor-1</description>
          <units>nanograms/milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109" spread="11"/>
                    <measurement group_id="O2" value="-25" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Trunk Fat</title>
        <time_frame>18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Recombinant Human Growth Hormone</title>
            <description>recombinant human growth hormone starting at 2 micrograms/kilograms/day subcutaneously and increased to maximum dose of 6 micrograms/kilograms/day subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo subcutaneously once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Trunk Fat</title>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="0.2"/>
                    <measurement group_id="O2" value="0.2" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fasting Glucose</title>
        <description>change in fasting glucose</description>
        <time_frame>18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Recombinant Human Growth Hormone</title>
            <description>recombinant human growth hormone starting at 2 micrograms/kilograms/day subcutaneously and increased to maximum dose of 6 micrograms/kilograms/day subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo subcutaneously once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fasting Glucose</title>
          <description>change in fasting glucose</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" spread="1"/>
                    <measurement group_id="O2" value="5" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Trunk to Extremity Ratio</title>
        <description>change in trunk to extremity ratio</description>
        <time_frame>18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Recombinant Human Growth Hormone</title>
            <description>recombinant human growth hormone starting at 2 micrograms/kilograms/day subcutaneously and increased to maximum dose of 6 micrograms/kilograms/day subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo subcutaneously once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Trunk to Extremity Ratio</title>
          <description>change in trunk to extremity ratio</description>
          <units>kilogram per kilogram</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="0.1"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Triglycerides</title>
        <description>Change in triglycerides</description>
        <time_frame>18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Recombinant Human Growth Hormone</title>
            <description>recombinant human growth hormone starting at 2 micrograms/kilograms/day subcutaneously and increased to maximum dose of 6 micrograms/kilograms/day subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo subcutaneously once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Triglycerides</title>
          <description>Change in triglycerides</description>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7" lower_limit="-43" upper_limit="41"/>
                    <measurement group_id="O2" value="0" lower_limit="-56" upper_limit="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Subcutaneous Adipose Tissue</title>
        <description>Change in subcutaneous adipose tissue</description>
        <time_frame>18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Recombinant Human Growth Hormone</title>
            <description>recombinant human growth hormone starting at 2 micrograms/kilograms/day subcutaneously and increased to maximum dose of 6 micrograms/kilograms/day subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo subcutaneously once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Subcutaneous Adipose Tissue</title>
          <description>Change in subcutaneous adipose tissue</description>
          <units>centimeters squared</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" spread="4"/>
                    <measurement group_id="O2" value="4" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in CD4 Cells</title>
        <description>Change in CD4 cells</description>
        <time_frame>18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Recombinant Human Growth Hormone</title>
            <description>recombinant human growth hormone starting at 2 micrograms/kilograms/day subcutaneously and increased to maximum dose of 6 micrograms/kilograms/day subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo subcutaneously once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in CD4 Cells</title>
          <description>Change in CD4 cells</description>
          <units>cells/microliter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19" spread="13"/>
                    <measurement group_id="O2" value="15" spread="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Logarithm HIV Viral Load</title>
        <description>Change in logarithm base 10 HIV viral load</description>
        <time_frame>18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Recombinant Human Growth Hormone</title>
            <description>recombinant human growth hormone starting at 2 micrograms/kilograms/day subcutaneously and increased to maximum dose of 6 micrograms/kilograms/day subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo subcutaneously once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Logarithm HIV Viral Load</title>
          <description>Change in logarithm base 10 HIV viral load</description>
          <units>log base 10 copies of RNA/milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0.1"/>
                    <measurement group_id="O2" value="0" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Lean Body Mass</title>
        <description>change in lean body mass</description>
        <time_frame>18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Recombinant Human Growth Hormone</title>
            <description>recombinant human growth hormone starting at 2 micrograms/kilograms/day subcutaneously and increased to maximum dose of 6 micrograms/kilograms/day subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo subcutaneously once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Lean Body Mass</title>
          <description>change in lean body mass</description>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.3"/>
                    <measurement group_id="O2" value="-0.5" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Quality of Life Score From the Medical Outcomes Study-HIV Survey From Baseline to 18 Months</title>
        <description>Change in quality of life score was measured by the Medical Outcomes Study-HIV (MOS-HIV)survey. The MOS-HIV asks patients to report on health-related quality of life and physical function from the past 4 days. The scoring range is 0-100, and a higher score indicates better quality of life.</description>
        <time_frame>18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Recombinant Human Growth Hormone</title>
            <description>recombinant human growth hormone starting at 2 micrograms/kilograms/day subcutaneously and increased to maximum dose of 6 micrograms/kilograms/day subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo subcutaneously once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Quality of Life Score From the Medical Outcomes Study-HIV Survey From Baseline to 18 Months</title>
          <description>Change in quality of life score was measured by the Medical Outcomes Study-HIV (MOS-HIV)survey. The MOS-HIV asks patients to report on health-related quality of life and physical function from the past 4 days. The scoring range is 0-100, and a higher score indicates better quality of life.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4" spread="3"/>
                    <measurement group_id="O2" value="-4" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Diastolic Blood Pressure</title>
        <description>Change in diastolic blood pressure</description>
        <time_frame>18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Recombinant Human Growth Hormone</title>
            <description>recombinant human growth hormone starting at 2 micrograms/kilograms/day subcutaneously and increased to maximum dose of 6 micrograms/kilograms/day subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo subcutaneously once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Diastolic Blood Pressure</title>
          <description>Change in diastolic blood pressure</description>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3" spread="1"/>
                    <measurement group_id="O2" value="4" spread="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Adiponectin</title>
        <description>Change in adiponectin</description>
        <time_frame>18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Recombinant Human Growth Hormone</title>
            <description>recombinant human growth hormone starting at 2 micrograms/kilograms/day subcutaneously and increased to maximum dose of 6 micrograms/kilograms/day subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo subcutaneously once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Adiponectin</title>
          <description>Change in adiponectin</description>
          <units>mcg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="0.3"/>
                    <measurement group_id="O2" value="0.5" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Carotid Intima Media Thickness (IMT)</title>
        <description>change in carotid intima media thickness (IMT)</description>
        <time_frame>18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Recombinant Human Growth Hormone</title>
            <description>recombinant human growth hormone starting at 2 micrograms/kilograms/day subcutaneously and increased to maximum dose of 6 micrograms/kilograms/day subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo subcutaneously once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Carotid Intima Media Thickness (IMT)</title>
          <description>change in carotid intima media thickness (IMT)</description>
          <units>millimeter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.003" spread="0.008"/>
                    <measurement group_id="O2" value="-0.003" spread="0.009"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Body Mass Index</title>
        <description>Change in body mass index</description>
        <time_frame>18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Recombinant Human Growth Hormone</title>
            <description>recombinant human growth hormone starting at 2 micrograms/kilograms/day subcutaneously and increased to maximum dose of 6 micrograms/kilograms/day subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo subcutaneously once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body Mass Index</title>
          <description>Change in body mass index</description>
          <units>kilogram/meters squared</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.2"/>
                    <measurement group_id="O2" value="0.1" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Extremity Fat</title>
        <description>Change in extremity fat</description>
        <time_frame>18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Recombinant Human Growth Hormone</title>
            <description>recombinant human growth hormone starting at 2 micrograms/kilograms/day subcutaneously and increased to maximum dose of 6 micrograms/kilograms/day subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo subcutaneously once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Extremity Fat</title>
          <description>Change in extremity fat</description>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.1"/>
                    <measurement group_id="O2" value="0.3" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in 2-hour Glucose</title>
        <description>Change in 2-hour glucose</description>
        <time_frame>18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Recombinant Human Growth Hormone</title>
            <description>recombinant human growth hormone starting at 2 micrograms/kilograms/day subcutaneously and increased to maximum dose of 6 micrograms/kilograms/day subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo subcutaneously once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in 2-hour Glucose</title>
          <description>Change in 2-hour glucose</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" spread="5"/>
                    <measurement group_id="O2" value="-4" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Systolic Blood Pressure</title>
        <description>Change in systolic blood pressure</description>
        <time_frame>18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Recombinant Human Growth Hormone</title>
            <description>recombinant human growth hormone starting at 2 micrograms/kilograms/day subcutaneously and increased to maximum dose of 6 micrograms/kilograms/day subcutaneously</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo subcutaneously once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Systolic Blood Pressure</title>
          <description>Change in systolic blood pressure</description>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5" spread="2"/>
                    <measurement group_id="O2" value="1" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>18 months</time_frame>
      <desc>1 participant in the growth hormone group dropped out of the study before ever receiving study drug and therefore was not included in the adverse event safety analysis.</desc>
      <group_list>
        <group group_id="E1">
          <title>Recombinant Human Growth Hormone</title>
          <description>recombinant human growth hormone starting at 2 micrograms/kilograms/day subcutaneously and increased to maximum dose of 6 micrograms/kilograms/day subcutaneously</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>placebo subcutaneously once a day</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>appendicitis requiring surgery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>hospitalization</sub_title>
                <description>hospitalization for confusion and transaminitis thought to be related to HIV disease progression</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>hip fracture requiring surgery</sub_title>
                <description>hip fracture requiring surgery</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>rectal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>anal cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>hyperglycemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>tingling and paresthesia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Janet Lo</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-724-9109</phone>
      <email>jlo@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

